Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading ...

Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...

Alumis plans to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Over ...

Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...

The cycle that goes wrong Normal skin replaces itself in roughly 28 to 30 days. A new keratinocyte forms at the base of the epidermis, migrates upward, flattens, loses its nucleus, and eventually ...

Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact ...

If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.

Zasocitinib was 2.5 times more effective than deucravacitinib at helping patients with plaque psoriasis achieve completely clear skin, based on the first head-to-head test.

PRNewswire/ -- (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), ...

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment ...